Judit Megyesi
Researcher
Also affiliated: The University of Texas MD Anderson Cancer Center (2013); University of Arizona (2019); Medical University of South Carolina (2019); University of Arkansas Medical Center (2001); Massachusetts General Hospital (2013); Southern Arizona VA Health Care System (2019); Central Arkansas Veterans Healthcare System (2002–2022); University of Applied Management Studies (2020); John L. McClellan Memorial Veterans Hospital (2019); The University of Texas Medical Branch at Galveston (1995–2008); The University of Tokyo (2004); Saitama Medical University (2013); The University of Osaka (2004)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Judit Megyesi's research investigates mechanisms of organ injury and protection, with a particular focus on kidney and muscle tissue. Her work has explored how specific deficiencies or interventions can alter the course of disease. For instance, she has published on how neutral ceramidase deficiency offers protection against cisplatin-induced acute kidney injury in mice. Additionally, her research has examined the impact of iron chelation in preventing age-related skeletal muscle sarcopenia in a genetic mouse model of aging. She has also investigated the protective effects of γ-tocotrienol against mitochondrial dysfunction and renal function decline following ischemia.
Megyesi's scholarly contributions are reflected in her metrics, including an h-index of 40 and over 5,000 citations from 77 publications. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including Oleg Karaduta, Sharda P. Singh, Sudhir V. Shah, and Chhanda Bose, on shared publications. Her recent activity indicates an ongoing engagement with her research areas.
Metrics
- h-index: 40
- Publications: 77
- Citations: 5,037
Selected Publications
-
Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging (2025)
-
Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury (2022)
-
γ-Tocotrienol Protects against Mitochondrial Dysfunction, Energy Deficits, Morphological Damage, and Decreases in Renal Functions after Renal Ischemia (2021)
-
C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury (2020)
-
Deletion of VDAC1 Hinders Recovery of Mitochondrial and Renal Functions After Acute Kidney Injury (2020)
-
Protein kinase Cα mediates recovery of renal and mitochondrial functions following acute injury (2019)
-
Complement C1r serine protease contributes to kidney fibrosis (2019)
-
Proximal Tubule β2-Adrenergic Receptor Mediates Formoterol-Induced Recovery of Mitochondrial and Renal Function after Ischemia-Reperfusion Injury (2019)
-
5-HT<sub>1F</sub> receptor regulates mitochondrial homeostasis and its loss potentiates acute kidney injury and impairs renal recovery (2018)
-
Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease (2018)
-
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury (2017)
-
Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis (2017)
-
Suramin Protects From Cisplatin‐Induced Acute Kidney Injury (2016)
-
Deletion of protein kinase C-ε attenuates mitochondrial dysfunction and ameliorates ischemic renal injury (2016)
-
Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak (2016)
Collaboration Network
Top Collaborators
- γ-Tocotrienol Protects against Mitochondrial Dysfunction, Energy Deficits, Morphological Damage, and Decreases in Renal Functions after Renal Ischemia
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
- Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging
- Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging
Similar Researchers
Based on overlapping research topics